EBITDA: Income before interest, taxes, depreciation and amortization.
Traws Pharma, Inc. (TRAW) had EBITDA of $-4.04M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-0.93M |
|
-- |
|
-- |
|
$4.05M |
|
$-4.05M |
|
$0.09M |
|
$-3.96M |
|
$-3.96M |
|
$-3.96M |
|
$-3.96M |
|
$-3.96M |
|
$-3.96M |
|
$-4.05M |
|
|
EBITDA |
$-4.04M |
8.82M |
|
8.82M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$9.62M |
|
$0.01M |
|
$2.82M |
|
$12.44M |
|
$7.89M |
|
-- |
|
$0.01M |
|
$7.90M |
|
$4.54M |
|
$1.97M |
|
$4.54M |
|
7.13M |
|
| Cash Flow Statement Financials | |
$-15.43M |
|
$-2.58M |
|
$3.05M |
|
$21.34M |
|
$6.42M |
|
$-14.92M |
|
$0.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.43M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-87.17% |
|
-200.71% |
|
-31.84% |
|
-87.17% |
|
$0.64 |
|
$-1.75 |
|
$-1.75 |
|